NDA 021902 · Ani Pharms
Veregen
Sinecatechins · Topical
NovelLast checked: Nov 19, 2026Latest source record: Dec 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 31, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 1 recruiting
FAERS reports
54
30 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2022.
Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses (1.2) . 1.1 Indication Veregen is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. 1.2 Limitations of Use The safety and effectiveness of Veregen have not been established for treatment beyond 16-weeks or for multiple treatment courses. The safety and effectiveness of Veregen in immunosuppressed patients have not been established.
Mechanism: The mode of action of Veregen involved in the clearance of genital and perianal warts is unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2007 Supplement 2 · Efficacy LetterLabel
- Oct 31, 2006 Original approval · Type 1 - New Molecular Entity NovelReviewLabelLetter
1 products under this application
- VEREGEN · SINECATECHINS 15% · OINTMENT, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sinecatechins" as an intervention, any sponsor and status, largest first.
- To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringPivotal-lookingActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04597359 · 360 participants (planned) · Start Oct 5, 2021 · Primary completion Dec 31, 2026
Drug: Placebo Administration; Sinecatechins · For: Prostate Carcinoma
Sites: Fairbanks, Alaska; Phoenix, Arizona; Fayetteville, Arkansas · 353 sites in all
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic KeratosisPivotal-lookingRecruiting
Aresus Pharma GmbHIndustry
NCT07137819 · 280 participants (planned) · Start Sep 4, 2024 · Primary completion Mar 2026
Drug: Topical treatment · For: Actinic Keratosis of Face and Scalp
Sites: Strausberg, Germany
- Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual MalesPivotal-lookingCompleted
Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
NCT04055142 · 108 participants · Start Sep 18, 2020 · Primary completion Jan 11, 2024
Drug: cidofovir 1% topical ointment; sinecatechins 10% topical ointment · For: High-grade Anal Intraepithelial Neoplasia
Sites: Barcelona, Spain
MediGeneIndustry
NCT01082302 · 43 participants · Start Jan 2010 · Primary completion Aug 2010
Drug: Polyphenon E (Veregen) 15% ointment · For: Genital Warts; Perianal Warts
Sites: Berlin, Germany
- Topical Green Tea Ointment in Treatment of Superficial Skin CancerPivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT02029352 · 42 participants · Start Nov 2014 · Primary completion Sep 2015
Drug: Sinecatechins 10%; Placebo · For: Carcinoma, Basal Cell
Sites: Maastricht, Netherlands
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT02147353 · 42 participants · Start Sep 2011 · Primary completion Dec 2012
Drug: Sinecatechins 15% Ointment; Cryotherapy alone · For: External Genital Warts
Sites: New York, New York
GTO Pharmaceutical, LLCAcademic, hospital or other
NCT03682601 · 32 participants · Start Aug 30, 2018 · Primary completion Feb 12, 2021
Drug: 5% sinecatechins ointment; Placebo and 1 more · For: Sexual Pain Disorders; Postmenopausal Symptoms; Vulvovaginal Atrophy and 7 more
Sites: New York, New York; Nyack, New York · 4 sites in all
MediGeneIndustry
NCT01490008 · 30 participants · Start Dec 2011 · Primary completion Mar 2012
Drug: Veregen · For: Anogenital Warts
Sites: Erfurt, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cellulitis6
- application site pain5
- drug ineffective5
- pain4
- product use issue4
- application site erythema3
- erythema3
- off label use3
- pruritus3
- rash3
- application site discharge2
- application site pruritus2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Veregen (Sinecatechins)
2024 spending
$223K
Beneficiaries
70
126 claims
Per beneficiary
$3,189
$51.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $235,043 |
| 2024 | $223,245 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial.
Kessels J, Voeten L, Nelemans P, et al. · JAMA Dermatol 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Sinecatechins ointment as a potential novel treatment for usual type vulval intraepithelial neoplasia: a single-centre double-blind randomised control study.
Yap J, Slade D, Goddard H, et al. · BJOG 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Interventions for anal canal intraepithelial neoplasia.
Pedersen TB, Pachler FR, Rosenberg J, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts.
On SC, Linkner RV, Haddican M, et al. · J Drugs Dermatol 2014 · Comparative Study, Randomized Controlled Trial
- Cellular signaling in sinecatechins-treated external genital and perianal warts: unraveling the mechanism of action of a botanical therapy.
Nguyen HP, Doan HQ, Rady P, et al. · Virol Sin 2015 · Clinical Trial, Phase III, Letter
- Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.
Tatti S, Swinehart JM, Thielert C, et al. · Obstet Gynecol 2008 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.